argenx SE – NASDAQ:ARGX

argenx SE stock price today

$656.89
+30.58
+4.88%
Financial Health
0
1
2
3
4
5
6
7
8
9

argenx SE stock price monthly change

+34.28%
month

argenx SE stock price quarterly change

+34.28%
quarter

argenx SE stock price yearly change

+62.04%
year

argenx SE key metrics

Market Cap
37.40B
Enterprise value
19.96B
P/E
-27.64
EV/Sales
48.59
EV/EBITDA
-27.51
Price/Sales
50.51
Price/Book
7.37
PEG ratio
0.43
EPS
-5.68
Revenue
1.40B
EBITDA
-231.29M
Income
-327.92M
Revenue Q/Q
82.98%
Revenue Y/Y
132.28%
Profit margin
-172.76%
Oper. margin
-175.37%
Gross margin
92.83%
EBIT margin
-175.37%
EBITDA margin
-16.42%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

argenx SE stock price history

argenx SE stock forecast

argenx SE financial statements

Average Price Target
Last Year

$660

Potential upside: 0.47%

Based on estimate of 2 analysts
  • Analysts Price target

  • Financials & Ratios estimates

argenx SE (NASDAQ:ARGX): Profit margin
Jun 2023 270.55M -94.36M -34.88%
Sep 2023 329.78M -72.64M -22.03%
Dec 2023 407.43M -99.31M -24.38%
Mar 2024 401.00M -61.59M -15.36%
argenx SE (NASDAQ:ARGX): Earnings per share (EPS)
2022-10-27 -5.32202 -4.26
2022-12-31 1.24 -0.69744
2023-03-02 -0.7 -0.7
argenx SE (NASDAQ:ARGX): Debt to assets
Jun 2023 3193791000 335.74M 10.51%
Sep 2023 0 0
Dec 2023 4542458000 444.95M 9.8%
Mar 2024 0 0
argenx SE (NASDAQ:ARGX): Cash Flow
Jun 2023 -258.49M 500.47M 62.38M
Sep 2023 0 0 0
Dec 2023 -69.55M -284.69M 1.27B
Mar 2024 0 0 0

argenx SE alternative data

argenx SE (NASDAQ:ARGX): Employee count
Sep 2023 843
Oct 2023 843
Nov 2023 843
Dec 2023 843
Jan 2024 843
Feb 2024 843
Mar 2024 1,148
Apr 2024 1,148
May 2024 1,148
Jun 2024 1,148
Jul 2024 1,148

argenx SE other data

63.05% +5.90%
of ARGX is owned by hedge funds
32.20M +3.26M
shares is hold by hedge funds
Insider Compensation
Mr. Timothy Van Hauwermeiren M.B.A., M.Sc., MSc, EMBA (1972) Chief Executive Officer & Executive Director
$1,130,000
Dr. David Lacey M.D. (1952) Advisor $56,510
Friday, 27 December 2024
globenewswire.com
Tuesday, 26 November 2024
globenewswire.com
Wednesday, 20 November 2024
globenewswire.com
Monday, 11 November 2024
https://thefly.com
globenewswire.com
businesswire.com
Tuesday, 5 November 2024
zacks.com
zacks.com
globenewswire.com
Thursday, 31 October 2024
seekingalpha.com
seekingalpha.com
globenewswire.com
Thursday, 24 October 2024
globenewswire.com
Tuesday, 15 October 2024
globenewswire.com
Friday, 4 October 2024
zacks.com
zacks.com
Tuesday, 24 September 2024
seekingalpha.com
Thursday, 19 September 2024
globenewswire.com
Friday, 6 September 2024
investors.com
zacks.com
Wednesday, 28 August 2024
globenewswire.com
Friday, 16 August 2024
zacks.com
Wednesday, 31 July 2024
zacks.com
zacks.com
Tuesday, 30 July 2024
zacks.com
zacks.com
Thursday, 25 July 2024
globenewswire.com
Thursday, 18 July 2024
globenewswire.com
Tuesday, 16 July 2024
globenewswire.com
businesswire.com
  • What's the price of argenx SE stock today?

    One share of argenx SE stock can currently be purchased for approximately $656.89.

  • When is argenx SE's next earnings date?

    Unfortunately, argenx SE's (ARGX) next earnings date is currently unknown.

  • Does argenx SE pay dividends?

    No, argenx SE does not pay dividends.

  • How much money does argenx SE make?

    argenx SE has a market capitalization of 37.40B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 198.56% to 1.23B US dollars. argenx SE made a loss 295.05M US dollars in net income (profit) last year or -$0.7 on an earnings per share basis.

  • What is argenx SE's stock symbol?

    argenx SE is traded on the NASDAQ under the ticker symbol "ARGX".

  • What is argenx SE's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of argenx SE?

    Shares of argenx SE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are argenx SE's key executives?

    argenx SE's management team includes the following people:

    • Mr. Timothy Van Hauwermeiren M.B.A., M.Sc., MSc, EMBA Chief Executive Officer & Executive Director(age: 53, pay: $1,130,000)
    • Dr. David Lacey M.D. Advisor(age: 73, pay: $56,510)
  • How many employees does argenx SE have?

    As Jul 2024, argenx SE employs 1,148 workers.

  • When argenx SE went public?

    argenx SE is publicly traded company for more then 8 years since IPO on 18 May 2017.

  • What is argenx SE's official website?

    The official website for argenx SE is argenx.com.

  • How can i contact argenx SE?

    argenx SE can be reached via phone at +31 10 703 8441.

  • What is argenx SE stock forecast & price target?

    Based on 2 Wall Street analysts` predicted price targets for argenx SE in the last 12 months, the avarage price target is $660. The average price target represents a 0.47% change from the last price of $656.89.

argenx SE company profile:

argenx SE

argenx.com
Exchange:

NASDAQ

Full time employees:

1,148

Industry:

Biotechnology

Sector:

Healthcare

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Willemstraat 5
Breda, 4811 AH

CIK: 0001697862
ISIN: NL0010832176
CUSIP: 04016X101